(MENAFN- Investor Brand Network) HeartBeam (NASDAQ: BEAT) , a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (“VECG”) platform for patient use at home, today announced that it will hold a conference call on Thursday, May 9, 2024, at 4:30 p.m. Eastern Time to discuss its results for the first quarter ended March 31, 2024. In addition, the company will provide regulatory updates, review ongoing initiatives, and detail anticipated 2024 milestones. HeartBeam CEO and Founder Branislav Vajdic, President Robert Eno and Consulting CFO Richard Brounstein will host the conference call and answer questions from attendees. A presentation will accompany the conference call and will be viewable during the webcast or accessed via the investor relations section of the company's
website . Those interested in calling in should dial 1-844-826-3035 (from the U.S.) or 1-412-317-5195 (from international locations), then enter the conference code 10188115. Additionally, interested parties should visit
to access the webcast. A telephone replay will be available approximately three hours after the call and will run through August 9, 2024.
To view the full press release, visit
About HeartBeam Inc.
HeartBeam is a cardiac technology company that has developed the first and only 3D-vector ECG platform intended for patient use at home. By applying a suite of proprietary algorithms to simplify vector electrocardiography (“VECG”), the HeartBeam platform enables patients and their clinicians to assess their cardiac symptoms quickly and easily, so care can be expedited, if required. HeartBeam AIMIGo(TM) is the first and only credit card-sized 12-lead output ECG device coupled with a smart phone app and cloud-based diagnostic software system to facilitate remote evaluation of cardiac symptoms. By collecting 3D signals of the heart's electrical activity, HeartBeam AIMIGo has the potential to provide unparalleled data for the development of AI algorithms. HeartBeam AIMIGo has not yet been cleared by the U.S. Food and Drug Administration (“FDA”) for marketing in the USA or other geographies. For more information, visit
.
NOTE TO INVESTORS:
The latest news and updates relating to BEAT are available in the company's newsroom at
About BioMedWire
BioMedWire
(“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the
Dynamic Brand Portfolio
@
IBN
that delivers :
(1) access to a vast network of wire solutions via
InvestorWire
to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ;
(2) article and
editorial syndication to 5,000+ outlets ;
(3) enhanced
press release enhancement
to ensure maximum impact ;
(4)
social media distribution
via IBN to millions of social media followers ;
and (5) a full array of tailored
corporate communications solutions . With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire,“Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:
/Disclaimer
BioMedWire
San Francisco, CA
415.949.5050 Office
...
BioMedWire is powered by
IBN
MENAFN25042024000224011066ID1108141437
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.